Novel consortium to address shortfall in innovative medicines for psychiatric disorders | PDF (274 KB)

p523 | doi:10.1038/nrd2939

Teaming up to tackle RNAi delivery challenge | PDF (320 KB)

p525 | doi:10.1038/nrd2940

Deal watch: J&J buys biotech with promising prostate cancer therapy | PDF (174 KB)

p528 | doi:10.1038/nrd2937

Trial watch: Novel obesity therapies set to attract spotlight in Q3 2009 | PDF (103 KB)

p529 | doi:10.1038/nrd2938

Inflammatory diseases: Targeting prostanoid receptors | PDF (164 KB)

p537 | doi:10.1038/nrd2932

Anti-obesity drugs: Improving sleep may promote weight loss | PDF (171 KB)

p538 | doi:10.1038/nrd2930

Neurodegenerative disorders: HDAC2 is the one | PDF (166 KB)

p538 | doi:10.1038/nrd2934

Anticancer drugs: Prioritizing targets | PDF (177 KB)

p539 | doi:10.1038/nrd2933

Mood disorders: Channel inhibitor shows antidepressant potential | PDF (204 KB)

p540 | doi:10.1038/nrd2931

Cell cycle kinases as therapeutic targets for cancer

Silvia Lapenna & Antonio Giordano

p547 | doi:10.1038/nrd2907

Aberrant activity of cell cycle protein kinases, leading to uncontrolled cell proliferation, is a hallmark of human cancer. Here, Lapenna and Giordano review recent progress in the modulation of specific protein kinase activity for the treatment of various cancers and identify novel strategies for the design of new agents.

• Abstract
• Full Text
• PDF (555 KB)
• Supplementary information

Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds

Yan Feng, Timothy J. Mitchison, Andreas Bender, Daniel W. Young & John A. Tallarico

p567 | doi:10.1038/nrd2876

Here, the authors summarize the current state of multi-parameter profiling technologies and how phenotypic profiling of small molecules provides important insights into their mechanisms of action, as well as a systems level understanding of biological pathways and their responses to drug treatments.

• Abstract
• Full Text
• PDF (526 KB)

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Dunyaporn Trachootham, Jerome Alexandre & Peng Huang

p579 | doi:10.1038/nrd2803

Drug resistance and the genomic instability of cancer cells hamper current gene-targeting therapeutic strategies for cancer. As Huang and colleagues discuss, targeting the unique biochemical properties of cancer cells — in particular, increased oxidative stress — might represent an alternative approach for the development of selective, redox-modulating anticancer agents.

• Abstract
• Full Text
• PDF (718 KB)

Translational medicine

p593 | doi:10.1038/nrd2925

• Abstract
• Full Text
• PDF (148 KB)